Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

Head & neck·2026
Same author

Reply to Borewad et al. Comment on "Rao et al. The Oncological Outcome of Postoperative Radiotherapy in Patients with Node-Negative Early-Stage (T1/T2/N0) Oral Squamous Cell Carcinoma and Perineural Invasion: A Meta-Analysis. <i>Cancers</i> 2025, <i>17</i>, 862".

Cancers·2026
Same author

Selection Criteria for De-Escalated Chemoradiotherapy for HPV-Related Oropharyngeal Cancer Based on Prognostic Biomarkers or Early Tumor Response to Therapy: A Narrative Review.

Diagnostics (Basel, Switzerland)·2026
Same author

Quantitative Imaging Advances in HPV-Positive Oropharyngeal Carcinoma.

Cancers·2026
Same author

Neutrophil to Lymphocyte and Lymphocyte to Monocyte Ratios Predict Improved Survival and Response to Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Larynx.

Head & neck·2025
Same author

Bayesian Monte Carlo Simulation Based on Systematic Review for Personalized Risk Stratification of Contralateral Lymph Node Metastasis in Oral Squamous Cell Carcinoma.

Diagnostics (Basel, Switzerland)·2025

Related Experiment Video

Updated: Jun 12, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Clinical heterogeneity and tumor control probability.

Avraham Eisbruch1

  • 1Department of Radiation Oncology, University of Michigan, Ann Arbor, USA. eisbruch@umich.edu

Acta Oncologica (Stockholm, Sweden)
|May 27, 2010
PubMed
Summary

Tumor control probability (TCP) models need to incorporate clinical factors like Human Papilloma Virus (HPV)-related oropharyngeal cancer. This ensures more accurate predictions and better patient stratification for cancer therapy.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Medical Physics

Background:

  • Tumor sensitivity heterogeneity impacts tumor control probability (TCP) models, leading to flattened dose-response curves.
  • Identifying key clinical factors influencing TCP is crucial for improving predictive models.

Purpose of the Study:

  • To highlight the necessity of integrating major clinical factors into TCP models.
  • To suggest patient and tumor stratification based on clinical factors for more precise TCP curves.

Main Methods:

  • Literature review focusing on oropharyngeal cancer therapy outcomes.
  • Analysis of clinical factors affecting treatment response.

Main Results:

  • Intensity-modulated radiotherapy (IMRT) offers dosimetric advantages, but Human Papilloma Virus (HPV)-related oropharyngeal cancer is a significant clinical factor.

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

  • HPV-related oropharyngeal cancer likely outweighs the benefits of IMRT's dosimetric superiority.

    • Conclusions:

    • Clinical factors, exemplified by HPV-related oropharyngeal cancer, are essential for the relevance and accuracy of TCP models.
    • TCP models must account for these clinical variables to yield steeper, more specific, and predictive dose-response curves.